3 results
Approved WMOCompleted
To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…
Approved WMOPending
The objective of this study is to evaluate the clinical efficacy, biological effects and safety of anifrolumab treatment in pSS.
Approved WMOPending
This study investigates the safety and efficacy of the new drug anifrolumab in patients with Lupus Nephritis. The effect of anifrolumab is compared with the effect of a placebo. Anifrolumab and placebo ("the study drug") are added to the…